Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EOC Gears To Evolve Into Integrated Oncology Company

Executive Summary

Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.

You may also be interested in...



Eddingpharm JV Gives Faes Smoother Route Into China

Eddingpharm, a Chinese specialty pharmaceutical company, is strengthening its international collaborations to bring more innovative products into the China market. The company has recently signed an agreement with Spain’s Faes Farma to establish a joint venture and commercialize Faes’ products in China.

China’s Eddingpharm Deal A Fresh Start For Ablynx’s Ozoralizumab

Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start for the anti-TNF nanobody after Pfizer backed out of a global deal in 2011.

Flying High: China’s Eddingpharm Takes Another Step With Its First Global Licensing Deal

In its latest deal, Eddingpharm continues its march forward from a third-party promotional partner for companies like GSK, to a China-based specialty pharma. After in-licensing a string of compounds last year, it has now added three more from ACT Biotech.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel